Free
Meeting Abstracts  |   May 1997
Isoflurane- and Halothane-mediated Dilation of Distal Bronchi in the Rat Depends on the Epithelium 
Author Notes
  • (Park) Assistant Professor of Anaesthesia.
  • (Dai) Research Fellow in Surgery.
  • (Lowenstein) Professor of Anaesthesia, Harvard Medical School; and Anesthetist-in-Chief, Beth Israel Deaconess Medical Center.
  • (Kocher) Assistant Professor of Pathology.
  • (Sellke) Associate Professor of Surgery.
  • Received from the Departments of Anesthesia and Critical Care, Surgery, and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. Supported in part by United States Public Health Service grant R29 HL-46716 and by a grant from the Beth Israel Anesthesia Foundation. Presented in part at the annual meeting of the American Society of Anesthesiologists, October 19–23, 1996, New Orleans, Louisiana.
  • Address reprint requests to Dr. Park: Department of Anesthesia and Critical Care, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, Massachusetts 02215. Address electronic mail to: kyungwonpark@mem.po.com.
Article Information
Meeting Abstracts   |   May 1997
Isoflurane- and Halothane-mediated Dilation of Distal Bronchi in the Rat Depends on the Epithelium 
Anesthesiology 5 1997, Vol.86, 1078-1087. doi:
Anesthesiology 5 1997, Vol.86, 1078-1087. doi:
Analogous to the endothelial modulation of vascular smooth muscle tone, [1 ] evidence has accumulated that respiratory epithelium may release substances that can modulate bronchial smooth muscle tone. Flavahan et al. [2 ] demonstrated in canine bronchi that removal of epithelium enhanced contractile responses to acetylcholine, histamine, or 5-hydroxytryptamine (5-HT) but reduced the relaxation response to isoproterenol. Similar findings have been reported in other species, including pigs, [3 ] guinea pigs, [4 ] and humans. [5 ]
The nature of the epithelium-derived relaxing factors (EpDRFs) has not been determined. It has been suggested that EpDRF may be a prostanoid, [6 ] specifically prostaglandin E2. [7,8 ] Whether EpDRF may be a guanylate cyclase activator such as nitric oxide or carbon monoxide has not been examined systematically.
Volatile anesthetics such as halothane and isoflurane traditionally have been considered potent bronchodilators [9 ] and have even been used to treat status asthmaticus. [10,11 ] In the only previous study that tested whether the bronchodilatory action of a volatile anesthetic depends on the release of EpDRF, Sayiner et al. [12 ] showed, in canine second-order and third-order bronchi, that the bronchodilatory effect of halothane was not epithelium dependent. However, as Stuart-Smith and Vanhoutte [13 ] have shown, epithelial dependence of the bronchomotor effect varies topographically in canine bronchi: Epithelial dependence of the bronchomotor response to contractile agents such as 5-HT and acetylcholine is seen in the second-order (lobar) and third-order (segmental) bronchi, but not in the fourth-order (subsegmental) bronchi, whereas epithelial dependence of the bronchomotor response to a dilatory agent such as isoproterenol is most prominent in the distal airways. In this investigation, we studied the epithelial dependence of bronchodilatory effects of isoflurane and halothane in vitro on isolated rat bronchial segments of the fourth order, in which we hypothesized that the epithelial dependence of the bronchodilatory effect would more likely be present than in more proximal airways. We also tried to determine whether the observed bronchodilatory effects were attenuated by inhibition of cyclooxygenase or NO synthase.
Materials and Methods 
Preparation of Bronchial Segments 
In accordance with the standards and with the approval of the institutional animal care and use committee, Wistar rats of either sex, weighing 100 to 150 g, were anesthetized by injecting 40 mg/kg ketamine and 5 mg/kg xylazine intraperitoneally. The lungs were removed quickly and placed in cold (4 degrees Celsius) modified Krebs buffer (120 mM NaCl, 5.9 mM KCl, 11.1 mM dextrose, 25 mM NaHCO3, 1.2 mM NaH2PO4, 1.2 mM MgSO4, and 2.5 mM CaCl2). Fourth-order bronchi were dissected free of surrounding tissues. Each bronchial segment (length, 0.5–1.5 mm; diameter, approximately 100 micro meter) was placed in a tissue chamber, cannulated with dual micropipettes (50–75 micro meter diameters), and secured with 10–0 sutures. The bronchial segment was bathed continuously with modified Krebs buffer, exposed to a 95% oxygen-5% carbon dioxide mixture, and maintained at 37 degrees Celsius with a pH of 7.4. The oxygen pressure in the tissue chamber exceeded 400 mmHg, and the bronchial segment was studied in a no-flow state. The bronchial segment was filled with Krebs buffer solution but was not pressurized above atmospheric pressure. All pharmacologic agents were added extraluminally. The bronchial segment was visualized with an inverted phase-contrast microscope (IMT-2; Olympus, Tokyo, Japan) connected to a video camera. The bronchial image was projected onto a television screen (Panasonic, Osaka, Japan). The bronchial lumen internal diameter was measured using an optical-density video detection system (Living Systems Instrumentation, Burlington, VT). Measurements of the lumen diameter were recorded. This tissue chamber system represents an adaptation of the vessel chamber system used for vasomotor studies, [14 ] a schematic of which was published previously. [14 ]
Stability of the Preparation 
To test for the stability of the bronchial preparation over time, the internal diameters of bronchial segments were followed for 2.5 h. Each segment reached an equilibration diameter within the first 5 min, and there was neither a spontaneous bronchodilatory nor a bronchoconstrictive tendency during this period.
To test for the stability of bronchomotor responses over time, six bronchial segments (internal diameter, 135 +/- 28 micro meter) were equilibrated in the tissue chamber for 30 min and then subjected successively to 10 micro Meter 5-HT, 1 micro Meter of the thromboxane analog U46619, 1 micro Meter histamine, and 100 mM KCl, with rinsing and re-equilibration for 5 min between interventions. The bronchial segments were subjected to the same set of interventions after 90 min in the tissue chamber. Magnitudes and direction of bronchomotor responses were compared.
In addition, to test for the stability of bronchomotor responses to volatile anesthetics, additional bronchial segments (n = 6; baseline size, 97 +/- 14 micro meter) were preconstricted with 10 micro Meter 5-HT and exposed to 2% isoflurane for 15 min, after 30 min of equilibration and again after 90 min of equilibration with rinsing and re-equilibration in between. Similar studies were performed for 2% halothane (n = 6; baseline size, 100 +/- 14 micro meter).
Epithelial Denudation 
To produce epithelial denudation, a fine Hamilton wire (Hamilton Co., Reno, NV) was passed repeatedly into the bronchial lumen. Epithelial denudation was confirmed histologically (Figure 1). To further validate our model of epithelial denudation, we compared the dilatory responses of epithelium-intact and epithelium-rubbed bronchial segments to the epithelium-dependent agent isoproterenol [2,3,13 ] and the epithelium-independent agent nitroprusside [4 ] after preconstriction with 10 micro Meter 5-HT.
Figure 1. Transverse sections of (A) epithelium-intact and (B) epithelium-rubbed rat bronchi of the fourth order. Each specimen was stained with 2% toluidine blue, fixed overnight in 2% glutaraldehyde, embedded in Epon, and then cut using an ultramicrotome. Magnification is x40. The epithelium-rubbed bronchial segment shows partial denudation of the epithelial layer. E = epithelium; M = smooth muscle.
Figure 1. Transverse sections of (A) epithelium-intact and (B) epithelium-rubbed rat bronchi of the fourth order. Each specimen was stained with 2% toluidine blue, fixed overnight in 2% glutaraldehyde, embedded in Epon, and then cut using an ultramicrotome. Magnification is x40. The epithelium-rubbed bronchial segment shows partial denudation of the epithelial layer. E = epithelium; M = smooth muscle.
Figure 1. Transverse sections of (A) epithelium-intact and (B) epithelium-rubbed rat bronchi of the fourth order. Each specimen was stained with 2% toluidine blue, fixed overnight in 2% glutaraldehyde, embedded in Epon, and then cut using an ultramicrotome. Magnification is x40. The epithelium-rubbed bronchial segment shows partial denudation of the epithelial layer. E = epithelium; M = smooth muscle.
×
Preparation of Sections for Histologic Analysis 
Each bronchial specimen was stained with 2% toluidine blue and fixed overnight in 2% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4). The next day, the tissue was washed in 0.1 M cacodylate buffer and enrobed in 2% Agar, which was then restained in 2% toluidine blue to make the Agar blocks more visible. Blocks were postfixed in 1% osmium tetroxide in 0.1 M cacodylate buffer for 1 h, washed in distilled water, incubated overnight in 2% uranyl acetate in water, washed with distilled water, and then dehydrated through ascending alcohols. Tissue was incubated in propylene oxide (a transitional solvent), infiltrated with several changes of 50% propylene oxide-50% Epon resin, followed by infiltration and embedding at 60 degrees Celsius in pure Epon. After 48 h of polymerization at 60 degrees Celsius, the blocks were trimmed manually, sectioned at 0.5-micro meter thickness with an ultramicrotome, and counterstained with 2% toluidine blue.
Experimental Protocol 
After 30 min of equilibration in the tissue chamber, a baseline measurement of the bronchial lumen diameter was obtained. The bronchus was preconstricted with 10 micro Meter 5-HT, a dose that had been found to produce consistent bronchoconstriction on preliminary studies. Bronchial segments were exposed to increasing concentrations of 0% to 3% isoflurane for 10 min at each concentration or 0% to 3% halothane for 15 min at each concentration by adding the anesthetic to the 95% carbon dioxide-5% oxygen mixture bubbling the Krebs buffer solution, using an in-line bubble-through vaporizer. Diameter changes at each concentration of the anesthetic were measured. Previously we showed [15 ] that in our tissue chamber system, less than 10 min for isoflurane and 15 min for halothane are needed to reach steady-state concentrations after introducing the respective anesthetic in the tissue chamber. We have also shown [15 ] that the millimolar concentrations and partial pressures of isoflurane and halothane remain consistently proportional to their concentrations in the gas mixture bubbled into the buffer solution. The anesthetic content in the gas mixture was monitored continuously using a Rascal II gas analyzer (Ohmeda, Salt Lake City, UT) that had been calibrated to industrial standards.
At the end of each experiment, the tissue chamber was flushed with fresh Krebs buffer and the bronchus was re-equilibrated at 37 degrees Celsius. Potassium chloride was added to achieve a final concentration of 100 mM, and the bronchial lumen diameter was measured. Only those bronchial segments that constricted by at least 15% in response to potassium chloride at the end of each experiment were considered still viable and included for data analysis. This represented exclusion of any bronchial segment that constricted less than the average amount by more than approximately 1 standard deviation. Potassium chloride has been shown to constrict epithelium-intact and epithelium-denuded bronchial segments equally well. [16 ]
To determine the epithelial dependence of volatile anesthetic-mediated bronchomotor effect, some bronchial segments were denuded of the epithelium by the technique just described. These segments were equilibrated, preconstricted with 5-HT, and then subjected to a volatile anesthetic, as described previously.
Similarly, other bronchial segments were pretreated with either 10 micro Meter of the cyclooxygenase inhibitor indomethacin or 10 micro Meter of the NO synthase inhibitor NG-nitro-L-arginine (L-NNA) in the buffer solution, before exposure to a volatile anesthetic, to determine whether a cyclooxygenase product or NO may be implicated as the cause of the bronchomotor effect.
All drugs were dissolved in ultradistilled water, but indomethacin was dissolved in ethanol and water. Ethanol had no significant bronchomotor effect at the concentration used in the study.
Statistical Analysis 
No animal contributed more than one bronchial segment to any one experimental group; therefore, the n value for each group represents the number of animals and the number of bronchial segments. Bronchomotor responses to various bronchomotor agents after 30 min of equilibration were compared with responses after 90 min of equilibration using the Student's t test (two tailed). Dose-response curves of rat bronchial segments to increasing concentrations of either isoflurane or halothane were analyzed by one-way analysis of variance (Scheffe's linear contrast) to test the null hypothesis that the anesthetic had no concentration-dependent effect on the bronchial lumen diameter. To determine whether isoflurane and halothane had different bronchodilating potencies at equivalent minimum alveolar concentration multiples, a multiple linear regression was performed and a P value was calculated for the identity of the anesthetic as a significant predictor of bronchodilation. The effects of epithelial denudation, pretreatment with indomethacin, or L-NNA on the anesthetic action were analyzed by two-way analysis of variance with a repeated measures factor, with post hoc Newmann-Keuls test for between-groups comparison when the initial analysis of variance yielded a significant P value. In addition, stratified z tests were performed to identify the concentrations at which the between-groups differences were significant. Responses of different experimental groups to 10 micro Meter of the preconstricting agent 5-HT or to viability testing with potassium chloride were compared using the Student's t test (two tailed). P < 0.05 was considered significant. All statistics were calculated using True Epistat software (Epistat Services, Richardson, TX). All data are presented as means +/- standard deviation.
Results 
Validation of Epithelial Denudation 
Histologic sections of bronchi subjected to repeated intraluminal abrasion showed significant, but incomplete, denudation of the epithelial layer (Figure 1). More vigorous abrasion resulting in complete epithelial denudation produced bronchial smooth muscle injury.
Epithelium-rubbed bronchial segments showed significantly attenuated dilatory response to the epithelium-dependent dilator isoproterenol compared with epithelium-intact segments (Figure 2(A))(P < 0.01). But there was no significant difference in the response to the epithelium-intact agent nitroprusside between epithelium-intact and epithelium-rubbed bronchial segments (Figure 2(B); P = 0.37). (Isoproterenol-epithelium intact: n = 6; baseline size, 115 +/- 21 micro meter; epithelium-rubbed: n = 6; baseline size, 118 +/- 20 micro meter. Nitroprusside-epithelium intact: n = 6; baseline size, 125 +/- 13 micro meter; epithelium rubbed: n = 6; baseline size, 116 +/- 16 micro meter).
Figure 2. Percentage relaxation versus logarithm of concentration of (A) isoproterenol and (B) nitroprusside. Epithelial rubbing attenuated dilatory response to the epithelium-dependent agonist isoproterenol (P <0.01) but not to the epithelium-independent agonist nitroprusside (P = 0.37). *P < 0.05 versus epithelium-intact control.
Figure 2. Percentage relaxation versus logarithm of concentration of (A) isoproterenol and (B) nitroprusside. Epithelial rubbing attenuated dilatory response to the epithelium-dependent agonist isoproterenol (P <0.01) but not to the epithelium-independent agonist nitroprusside (P = 0.37). *P < 0.05 versus epithelium-intact control.
Figure 2. Percentage relaxation versus logarithm of concentration of (A) isoproterenol and (B) nitroprusside. Epithelial rubbing attenuated dilatory response to the epithelium-dependent agonist isoproterenol (P <0.01) but not to the epithelium-independent agonist nitroprusside (P = 0.37). *P < 0.05 versus epithelium-intact control.
×
Stability of Bronchomotor Responses 
We found no significant difference in the respective responses of the bronchial segments to 5-HT, U46619, histamine, or potassium chloride after 30 min of equilibration compared with after 90 min of equilibration (P > 0.10, 0.75, 0.40, 0.59, respectively;Figure 3(A)). Neither was there a significant difference in the respective responses of the 5-HT-preconstricted bronchial segments to 2% isoflurane or 2% halothane after 30 min of equilibration compared with after 90 min of equilibration (P = 0.32 and 0.85, respectively;Figure 3(B)).
Figure 3. Comparison of the responses of (A) the bronchial segments to constrictive agents: 10 micro Meter 5-hydroxytryptamine, 1 micro Meter U46619, 1 micro Meter histamine, or 100 mM KCl; and (B) the 5-hydroxytryptamine-preconstricted bronchial segments to 2% isoflurane or 2% halothane after 30 min of equilibration versus after 90 min of equilibration. There was no significant difference between the two time points, demonstrating stability of the bronchomotor response over time.
Figure 3. Comparison of the responses of (A) the bronchial segments to constrictive agents: 10 micro Meter 5-hydroxytryptamine, 1 micro Meter U46619, 1 micro Meter histamine, or 100 mM KCl; and (B) the 5-hydroxytryptamine-preconstricted bronchial segments to 2% isoflurane or 2% halothane after 30 min of equilibration versus after 90 min of equilibration. There was no significant difference between the two time points, demonstrating stability of the bronchomotor response over time.
Figure 3. Comparison of the responses of (A) the bronchial segments to constrictive agents: 10 micro Meter 5-hydroxytryptamine, 1 micro Meter U46619, 1 micro Meter histamine, or 100 mM KCl; and (B) the 5-hydroxytryptamine-preconstricted bronchial segments to 2% isoflurane or 2% halothane after 30 min of equilibration versus after 90 min of equilibration. There was no significant difference between the two time points, demonstrating stability of the bronchomotor response over time.
×
Bronchomotor Effects of Volatile Anesthetics 
We found no significant difference in the magnitude of preconstriction produced by 10 micro Meter 5-HT, among any of the experimental groups (Table 1).
Table 1. Percent Contraction (Percent Decrease in Diameter from Baseline Equilibration Diameter) to KCl (Viability Testing) and to 5-HR 10 micro Meter (Preconstriction) of Various Experimental Groups of Rat Bronchial Segments 
Image not available
Table 1. Percent Contraction (Percent Decrease in Diameter from Baseline Equilibration Diameter) to KCl (Viability Testing) and to 5-HR 10 micro Meter (Preconstriction) of Various Experimental Groups of Rat Bronchial Segments 
×
Both isoflurane and halothane showed concentration-dependent bronchodilatory effects on 5-HT-preconstricted rat bronchial segments (Figure 4and Figure 5; P < 0.001 for either anesthetic)(control bronchi-for isoflurane: n = 6; baseline diameter, 129 +/- 18 micro meter; for halothane: n = 7; baseline diameter, 99 +/- 24 micro meter). At equivalent minimum alveolar concentration multiples, [17 ] isoflurane and halothane appeared to be equipotent (P = 0.75;Figure 6).
Figure 4. Relaxation of the 5-hydroxytryptamine-preconstricted bronchial segments to increasing concentrations of isoflurane: control, after epithelial rubbing, after pretreatment with NG-nitro-L-arginine (L-NNA), or after pretreatment with indomethacin. Isoflurane-mediated bronchodilation was significantly attenuated after epithelial rubbing (P < 0.01) or after pretreatment with L-NNA (P <0.005) or indomethacin (P < 0.02). Attenuation after L-NNA was significantly greater than after indomethacin (P < 0.05). #P < 0.05 versus control. *P < 0.05 between L-NNA pretreatment and indomethacin pretreatment. (One minimum alveolar concentration of isoflurane in rats was considered 1.20%. [17 ])
Figure 4. Relaxation of the 5-hydroxytryptamine-preconstricted bronchial segments to increasing concentrations of isoflurane: control, after epithelial rubbing, after pretreatment with NG-nitro-L-arginine (L-NNA), or after pretreatment with indomethacin. Isoflurane-mediated bronchodilation was significantly attenuated after epithelial rubbing (P < 0.01) or after pretreatment with L-NNA (P <0.005) or indomethacin (P < 0.02). Attenuation after L-NNA was significantly greater than after indomethacin (P < 0.05). #P < 0.05 versus control. *P < 0.05 between L-NNA pretreatment and indomethacin pretreatment. (One minimum alveolar concentration of isoflurane in rats was considered 1.20%. [17])
Figure 4. Relaxation of the 5-hydroxytryptamine-preconstricted bronchial segments to increasing concentrations of isoflurane: control, after epithelial rubbing, after pretreatment with NG-nitro-L-arginine (L-NNA), or after pretreatment with indomethacin. Isoflurane-mediated bronchodilation was significantly attenuated after epithelial rubbing (P < 0.01) or after pretreatment with L-NNA (P <0.005) or indomethacin (P < 0.02). Attenuation after L-NNA was significantly greater than after indomethacin (P < 0.05). #P < 0.05 versus control. *P < 0.05 between L-NNA pretreatment and indomethacin pretreatment. (One minimum alveolar concentration of isoflurane in rats was considered 1.20%. [17 ])
×
Figure 5. Relaxation of the 5-hydroxytryptamine-preconstricted bronchial segments to increasing concentrations of halothane: control, after epithelial rubbing, after pretreatment with NG-nitro-L-arginine (L-NNA), or after pretreatment with indomethacin. Halothane-mediated bronchodilation was significantly attenuated after epithelial rubbing (P < 0.01) or after pretreatment with L-NNA (P <0.05) or indomethacin (P < 0.001). Attenuation after L-NNA was significantly less than after indomethacin (P < 0.01). #P < 0.05 versus control. *P < 0.05 between L-NNA pretreatment and indomethacin pretreatment. (One minimum alveolar concentration of halothane in rats was considered 0.88%. [17 ])
Figure 5. Relaxation of the 5-hydroxytryptamine-preconstricted bronchial segments to increasing concentrations of halothane: control, after epithelial rubbing, after pretreatment with NG-nitro-L-arginine (L-NNA), or after pretreatment with indomethacin. Halothane-mediated bronchodilation was significantly attenuated after epithelial rubbing (P < 0.01) or after pretreatment with L-NNA (P <0.05) or indomethacin (P < 0.001). Attenuation after L-NNA was significantly less than after indomethacin (P < 0.01). #P < 0.05 versus control. *P < 0.05 between L-NNA pretreatment and indomethacin pretreatment. (One minimum alveolar concentration of halothane in rats was considered 0.88%. [17])
Figure 5. Relaxation of the 5-hydroxytryptamine-preconstricted bronchial segments to increasing concentrations of halothane: control, after epithelial rubbing, after pretreatment with NG-nitro-L-arginine (L-NNA), or after pretreatment with indomethacin. Halothane-mediated bronchodilation was significantly attenuated after epithelial rubbing (P < 0.01) or after pretreatment with L-NNA (P <0.05) or indomethacin (P < 0.001). Attenuation after L-NNA was significantly less than after indomethacin (P < 0.01). #P < 0.05 versus control. *P < 0.05 between L-NNA pretreatment and indomethacin pretreatment. (One minimum alveolar concentration of halothane in rats was considered 0.88%. [17 ])
×
Figure 6. Relaxation of the 5-hydroxytryptamine-preconstricted bronchial segments to increasing concentrations of isoflurane or halothane expressed as minimum alveolar concentration multiples (MAC). The two anesthetics appear to be equipotent bronchodilators at equivalent MAC multiples. (One MAC in rats was considered 1.20% isoflurane or 0.88% halothane. [17 ])
Figure 6. Relaxation of the 5-hydroxytryptamine-preconstricted bronchial segments to increasing concentrations of isoflurane or halothane expressed as minimum alveolar concentration multiples (MAC). The two anesthetics appear to be equipotent bronchodilators at equivalent MAC multiples. (One MAC in rats was considered 1.20% isoflurane or 0.88% halothane. [17])
Figure 6. Relaxation of the 5-hydroxytryptamine-preconstricted bronchial segments to increasing concentrations of isoflurane or halothane expressed as minimum alveolar concentration multiples (MAC). The two anesthetics appear to be equipotent bronchodilators at equivalent MAC multiples. (One MAC in rats was considered 1.20% isoflurane or 0.88% halothane. [17 ])
×
Isoflurane-mediated bronchodilation was attenuated but not abolished by pretreatment with either indomethacin (n = 7; baseline diameter, 120 +/- 21 micro meter; P < 0.02) or L-NNA (n = 7; baseline diameter, 98 +/- 16 micro meter; P < 0.005) or by epithelial denudation (n = 5; baseline diameter, 108 +/- 17 micro meter; P < 0.01;Figure 4). The attenuating effect of L-NNA pretreatment was significantly greater than that of indomethacin pretreatment (P < 0.05).
Similarly, halothane-mediated bronchodilation was attenuated but not abolished by pretreatment with either indomethacin (n = 7; baseline diameter, 107 +/- 24 micro meter; P < 0.001) or by L-NNA (n = 8; baseline diameter, 94 +/- 14 micro meter; P < 0.05), or by epithelial denudation (n = 6; baseline diameter, 99 +/- 20 micro meter; P < 0.01;Figure 5). Unlike with isoflurane, the attenuating effect of L-NNA pretreatment on halothane-mediated bronchodilation was significantly less than that of indomethacin pretreatment (P < 0.01).
We found no significant difference in responses to potassium chloride, used to test bronchial viability, among any of the experimental groups (Table 1). Specifically, there was no significant difference between the epithelium-intact and epithelium-denuded segments.
Discussion 
The main findings of our study are that bronchodilatory effects of isoflurane and halothane depend at least partially on the epithelium in subsegmental rat bronchi, and that these effects appear to be mediated by both a cyclooxygenase product and NO.
The bronchomotor effects of volatile anesthetics in vivo are multiple and complex. [9 ] All of them increase airway resistance to some extent because of loss of lung volume on induction. [9,18 ] However, the overall effect in vivo is bronchodilation for isoflurane, halothane, and enflurane in human beings and in dogs. [18–22 ] Our in vitro finding is consistent with those of earlier in vivo studies and shows a direct bronchodilatory effect of isoflurane and halothane on rat bronchi.
A role of the respiratory epithelium in modulating bronchoconstriction or enhancing bronchodilation was first suggested by Flavahan et al. [2 ] They demonstrated in rings of canine bronchi that removal of the epithelium increased contractile responses to acetylcholine, histamine, and 5-HT and decreased relaxation responses to isoproterenol. Subsequent works in the same laboratory and in others produced similar results in several species, including humans. [3–5,13,23–25 ] The structure of the respiratory epithelium changes progressively from pseudostratified, columnar cells of the large airways to thinner, less pseudostratified and simple cuboidal cells of the bronchioles, and finally to squamous cells in the alveoli. [23 ] Because of the varying structure of the respiratory epithelium, the role of epithelium in bronchomotion may vary topographically. In dogs, removing the epithelium enhances the effect of the contractile agonists in the large airways, whereas in small airways the major effect is to decrease relaxation to isoproterenol. [13 ] Such a distinction is not observed in porcine airways: Removal of epithelium has a comparable effect on isoproterenol-mediated relaxation and acetylcholine- or histamine-mediated contraction of porcine airways of different orders. [3 ] Although the role of the epithelium in modulating bronchomotion appears established, its exact nature may vary with the species, airway order, and perhaps experimental conditions.
In the present study, we used isolated rat bronchi of the fourth order, where the pseudostratified epithelium still predominates. One limitation of our experimental preparation is that our denudation technique resulted in incomplete and possibly variable amounts of denudation. Consequently, we cannot state unequivocally that the mild residual bronchodilatory effect of the anesthetics on the rubbed segments was due to incomplete epithelial removal or to an epithelium-independent component of bronchodilation. However, the epithelium-rubbed bronchial segments clearly showed significantly attenuated relaxation to isoflurane and halothane and to the known epithelium-dependent agent isoproterenol. [2,13 ] The decrease in bronchodilation with epithelial rubbing was not due to mechanical damage to the muscle layer, because the contractile responses to 10 micro Meter 5-HT and KCl and the dilatory responses to the known epithelium-independent agent nitroprusside [4 ] of epithelium-rubbed bronchial segments remained intact and comparable to the responses of unrubbed segments. Therefore the bronchodilatory effects of isoflurane and halothane on distal bronchi depend, at least partially, on the epithelium.
In the only previous study examining epithelial dependence of volatile anesthetic-mediated bronchodilation, Sayiner et al. [12 ] examined epithelial dependence of the bronchodilatory effect of halothane in canine bronchi of the second and third orders. They found that the ability of halothane 1 or 2 minimum alveolar concentration to relax carbachol-preconstricted bronchi was not affected by epithelium removal and that halothane caused equivalent rightward shifts of the concentration-response curves to acetylcholine and 5-HT, regardless of whether epithelium was present. Thus they concluded that the bronchodilatory effect of halothane was epithelium independent. In contrast, in our study with fourth-order rat bronchi, the effects of both halothane and isoflurane were strongly epithelium dependent. The apparent disparity between Sayiner et al.'s findings and our own is probably explained by topographic variation in epithelium dependence of bronchomotor effects and by differences in species and experimental methods.
Epithelial dependence of isoflurane- and halothane-mediated bronchodilation appeared to be mediated by both NO and a prostanoid. Coupled release of or synergism between NO and a prostanoid has been described in many biological systems. Examples include agonist-induced vasodilation, [26 ] flow- or shear stress-induced vasodilation, [27 ] and modulation of platelet aggregation. [28 ] Modulation of bronchomotion appears to be another system in which NO and a prostanoid work in conjunction.
The fact that EpDRF or one form of EpDRF may be a prostanoid has been demonstrated in guinea pigs, [29 ] dogs, [7 ] and humans. [8,30 ] Specifically, prostaglandin E2appears to be the most important mediator in dogs [7 ] and humans, [8,30 ] with prostaglandin I2possibly providing a synergistic effect. [7 ] The role of prostaglandin E2or I2has been disputed in guinea pigs. [29 ] Our findings are consistent with the fact that in rats, a prostanoid may be one of the EpDRFs.
Whether NO may be an EpDRF has not been examined specifically before. There is some suggestive evidence supporting this postulate, however. Ilhan and Sahin [31 ] used a bioassay to show that tracheal epithelium can produce a relaxing factor, which is not a product of cyclooxygenase and which can relax vascular smooth muscle. Furthermore, NO donors such as sodium nitroprusside and S-nitrosothiols have been shown to relax bronchial smooth muscles of pigs [3 ] and humans [32 ]; this is further corroborated in rats in our study. However, whether bronchodilation by NO is by activation of guanylate cyclase and generation of cyclic guanosine monophosphate (as in the case of vascular smooth muscle) or by an unknown, cyclic guanosine monophosphate-independent mechanism has been debated. [32,33 ]
Whereas the bronchodilatory effect of isoflurane and halothane may be partially mediated via generation of NO, the effects of the volatile anesthetics on the NO-cyclic guanosine monophosphate pathway in other tissue systems may be somewhat different. In the vascular system, the dilatory effect of isoflurane on conductance vessels has been reported to depend on the endothelium in the coronary circulation of rabbits [14 ] and dogs [34 ] but independent in the rat aorta [35 ] and canine cerebral arteries. [36 ] Further, volatile anesthetics have been demonstrated to attenuate agonist-induced NO-mediated vasodilation in both conductance arteries [37–39 ] and resistance arteries, [40 ] although the exact site of attenuation has been debated. Finally volatile anesthetics have been suggested to suppress the formation or action of NO in the neural tissues, thereby producing an anesthetic state. [41 ] The relation between volatile anesthetics and NO is complex and variable, depending on the tissue type and perhaps on species and experimental conditions.
Although the bronchomotor effects of both isoflurane and halothane are epithelium dependent, the relative contributions of a cyclooxygenase product and NO appear different for the two anesthetics. Namely isoflurane-mediated bronchodilation is more dependent on NO than on a bronchodilatory prostanoid, whereas the opposite is true for halothane. Therefore, even though the two anesthetics appeared to be equipotent bronchodilators at equivalent minimum alveolar concentrations in our model, they may have different potencies in circumstances of selective prostanoid or NO suppression.
In certain patients with bronchial hyperreactivity, such as those with asthma or exposure to an allergen or respiratory virus, focal epithelial damage or inflammation may be apparent. [16,42 ] A decrease in epithelial production of EpDRF may contribute to bronchial hyperreactivity, along with other causes such as a decrease in baseline airway caliber, autonomic dysfunction, and alterations in the bronchial smooth muscle itself. We can speculate that to the extent that the bronchodilatory effects of isoflurane and halothane are epithelium dependent, these anesthetics may not be as effective in patients with respiratory epithelial dysfunction in dilating the airways as in healthy persons. If epithelial dependence of volatile anesthetic-mediated bronchodilation is prominent primarily in distal airways even in humans, any beneficial effect of the anesthetics in dilating asthmatic airways may be evident mainly in the proximal airways. Further studies are needed for cross-species validation and using bronchial segments with preexisting airways disease.
In summary, we have shown in rat bronchial segments of the fourth order that isoflurane and halothane have direct, concentration-dependent bronchodilatory effects and that these effects depend at least partially on the epithelium. NO and a prostanoid may mediate the bronchodilatory effects of these anesthetics.
The authors thank Dan Brown for assistance in preparing bronchial sections for histologic analysis, Hang Lee, Ph.D., of Harvard Medical School for help with the statistical analysis, and Leo Hannenberg for assistance with computer software.
References 
References 
Moncada S, Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329:2002-12.
Flavahan NA, Aarhus LL, Rimele TJ, Vanhoutte PM: Respiratory epithelium inhibits bronchial smooth muscle tone. J Appl Physiol 1985; 58:834-8.
Stuart-Smith K, Vanhoutte PM: Airway epithelium modulates the responsiveness of porcine bronchial smooth muscle tone. J Appl Physiol 1988; 65:721-7.
Burgaud JL, Javellaud J, Oudart N: Do perfused small caliber airways of guinea-pig release an epithelium-dependent relaxing factor? Pulmonary Pharmacology 1993; 6:217-24.
Knight DA, Adcock JA, Phillips MJ, Thompson PJ: The effect of epithelium removal on human bronchial smooth muscle responsiveness to acetylcholine and histamine. Pulmonary Pharmacology 1990; 3:198-202.
Bramley AM, Piper PJ: Bradykinin-induced responses of human bronchial tissues. Modulation by epithelial removal and indomethacin. Ann N Y Acad Sci 1991; 629:451-4.
Yu XY, Hubbard W, Spannhake EW: Inhibition of canine tracheal smooth muscle by mediator from cultured bronchial epithelial cells. Am J Physiol 1992; 262:L229-34.
Knight DA, Stewart GA, Thompson PJ: Prostaglandin E2, but not prostacyclin inhibits histamine-induced contraction of human bronchial smooth muscle. Eur J Pharmacol 1995; 272:13-9.
Stevens WC, Kingston HG: Inhalation anesthesia. Clinical Anesthesia. Edited by Barash PG, Cullen BF, Stoelting RK. Philadelphia, JB Lippincott, 1989, pp 293-321.
Bierman MI, Brown M, Muren O, Keenan RL, Galuser FL: Prolonged isoflurane anesthesia in status asthmaticus. Crit Care Med 1986; 14:832-3.
Maltais F, Sovilj M, Goldberg P, Gottfried SB: Respiratory mechanics in status asthmaticus. Effects of inhalational anesthesia. Chest 1994; 106:1401-6.
Sayiner A, Lorenz RR, Warner DO, Rehder K: Bronchodilation by halothane is not modulated by airway epithelium. Anesthesiology 1991; 75:75-81.
Stuart-Smith K, Vanhoutte PM: Heterogeneity in the effects of epithelium-removal in the canine bronchial tree. J Appl Physiol 1987; 63:2510-5.
Park KW, Dai HB, Lowenstein E, Darvish A, Sellke FW: Heterogeneous vasomotor responses of rabbit coronary microvessels to isoflurane. Anesthesiology 1994; 81:1190-7.
Park KW, Dai HB, Lowenstein E, Sellke FW: Vasomotor responses of rat coronary arteries to isoflurane and halothane depend on preexposure tone and vessel size. Anesthesiology 1995; 83:1323-30.
Vanhoutte PM: Epithelium-derived relaxing factor(s) and bronchial reactivity. J Allergy Clin Immunol 1989; 83:855-61.
Vitez TS, White PF, Eger EI II: Effects of hypothermia on halothane MAC and isoflurane MAC in the rat. Anesthesiology 1974; 41:80-1.
Heneghan CPH, Bergman NA, Jordan C, Lehane JR, Catley DM: Effect of isoflurane on bronchomotor tone in man. Br J Anaesth 1986; 58:24-8.
Hirshman CA, Bergman NA: Halothane and enflurane protect against bronchospasm in an asthma dog model. Anesth Analg 1978; 57:629-33.
Hirshman CA, Edelstein G, Peetz S, Wayne R, Downes H: Mechanism of action of inhalational anesthesia on airways. Anesthesiology 1982; 56:107-11.
Coon RL, Kampine JP: Hypocapnic bronchoconstriction and inhalation anesthetics. Anesthesiology 1975; 43:635-41.
Hickey RF, Graf PD, Nadel JA, Larson CP: The effects of halothane and cyclopropane on total pulmonary resistance in the dog. Anesthesiology 1969; 31:334-43.
Hay DWP, Raeburn D, Fedan JS: Regional differences in reactivity and in the influence of the epithelium on canine intrapulmonary bronchial smooth muscle responsiveness. Eur J Pharmacol 1987; 141:363-70.
Prie S, Cadieux A, Sirois P: Removal of guinea pig bronchial and tracheal epithelium potentiates the contractions to leukotrienes and histamine. Eicosanoids 1990; 3:29-37.
Barnes PJ, Cuss FM, Palmer JB: The effect of airway epithelium on smooth muscle contractility in bovine trachea. Br J Pharmacol 1985; 86:685-91.
De Nucci G, Gryglewski RJ, Warner TD, Vane JR: Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc Natl Acad Sci USA 1988; 85:2334-8.
Melkumyants AM, Balashov SA, Khayutin VM: Control of arterial lumen by shear stress on endothelium. News Physiol Sci 1995; 10:204-10.
Houston DS, Robinson P, Gerrard JM: Inhibition of intravascular platelet aggregation by endothelium-derived relaxing factor: reversal by red blood cells. Blood 1990; 76:953-8.
Hay DWP, Muccitelli RM, Horstmeyer DL, Raeburn D: Is the epithelium-derived inhibitory factor in guinea pig trachea a prostanoid? Prostaglandins 1988; 35:625-37.
Knight DA, Stewart GA, Lai ML, Thompson PJ: Epithelium-derived inhibitory prostaglandins modulate human bronchial smooth muscle responses to histamine. Eur J Pharmacol 1995; 272:1-11.
Ilhan M, Sahin I: Tracheal epithelium releases a vascular smooth muscle relaxant factor: demonstration by bioassay. Eur J Pharmacol 1986; 131:293-6.
Gaston B, Drazen JM, Jansen A, Sugarbaker DA, Loscalzo J, Richards W, Stamler JS: Relaxation of human bronchial smooth muscle by S-nitrosothiols in vitro. J Pharmacol Exp Ther 1994; 268:978-84.
Wong WS, Roman CR, Fleisch JH: Differential relaxant responses of guinea-pig lung strips and bronchial rings to sodium nitroprusside: a mechanism independent of cGMP formation. J Pharm Pharmacol 1995; 47:757-61.
Blaise G, Sill JC, Nugent M, Van Dyke RA, Vanhoutte PM: Isoflurane causes endothelium-dependent inhibition of contractile responses of canine coronary arteries. Anesthesiology 1987; 67:513-7.
Brendel JK, Johns RA: Isoflurane does not vasodilate rat thoracic aortic rings by endothelium-derived relaxing factor or other cyclic GMP-mediated mechanisms. Anesthesiology 1992; 77:126-31.
Flynn NM, Buljubasic N, Bosnjak ZJ, Kampine JP: Isoflurane produces endothelium-independent relaxation in canine middle cerebral arteries. Anesthesiology 1992; 76:461-7.
Muldoon SM, Hart JL, Bowen KA, Freas W: Attenuation of endothelium-mediated vasodilation by halothane. Anesthesiology 1988; 68:31-7.
Zuo Z, Tichotsky A, Johns RA: Halothane and isoflurane inhibit vasodilation due to constitutive but not inducible nitric oxide synthase: implications for the site of anesthetic inhibition of the nitric oxide/guanylyl cyclase signalling pathway. Anesthesiology 1996; 84:1156-65.
Jing M, Bina S, Verma A, Hart JL, Muldoon SM: Effects of halothane and isoflurane on carbon monoxide-induced relaxations in the rat aorta. Anesthesiology 1996; 85:347-54.
Park KW, Dai HB, Lowenstein E, Darvish A, Sellke FW: Isoflurane and halothane attenuate endothelium-dependent vasodilation in rat coronary microvessels. Anesth Analg 1997; 84:278-84.
Nakamura K, Mori K: Nitric oxide and anesthesia. Anesth Analg 1993; 77:877-9.
Boushey HA, Holtzman MJ, Sheller JR, Nadel JA: Bronchial hyperreactivity. Am Rev Respir Dis 1980; 121:389-413.
Figure 1. Transverse sections of (A) epithelium-intact and (B) epithelium-rubbed rat bronchi of the fourth order. Each specimen was stained with 2% toluidine blue, fixed overnight in 2% glutaraldehyde, embedded in Epon, and then cut using an ultramicrotome. Magnification is x40. The epithelium-rubbed bronchial segment shows partial denudation of the epithelial layer. E = epithelium; M = smooth muscle.
Figure 1. Transverse sections of (A) epithelium-intact and (B) epithelium-rubbed rat bronchi of the fourth order. Each specimen was stained with 2% toluidine blue, fixed overnight in 2% glutaraldehyde, embedded in Epon, and then cut using an ultramicrotome. Magnification is x40. The epithelium-rubbed bronchial segment shows partial denudation of the epithelial layer. E = epithelium; M = smooth muscle.
Figure 1. Transverse sections of (A) epithelium-intact and (B) epithelium-rubbed rat bronchi of the fourth order. Each specimen was stained with 2% toluidine blue, fixed overnight in 2% glutaraldehyde, embedded in Epon, and then cut using an ultramicrotome. Magnification is x40. The epithelium-rubbed bronchial segment shows partial denudation of the epithelial layer. E = epithelium; M = smooth muscle.
×
Figure 2. Percentage relaxation versus logarithm of concentration of (A) isoproterenol and (B) nitroprusside. Epithelial rubbing attenuated dilatory response to the epithelium-dependent agonist isoproterenol (P <0.01) but not to the epithelium-independent agonist nitroprusside (P = 0.37). *P < 0.05 versus epithelium-intact control.
Figure 2. Percentage relaxation versus logarithm of concentration of (A) isoproterenol and (B) nitroprusside. Epithelial rubbing attenuated dilatory response to the epithelium-dependent agonist isoproterenol (P <0.01) but not to the epithelium-independent agonist nitroprusside (P = 0.37). *P < 0.05 versus epithelium-intact control.
Figure 2. Percentage relaxation versus logarithm of concentration of (A) isoproterenol and (B) nitroprusside. Epithelial rubbing attenuated dilatory response to the epithelium-dependent agonist isoproterenol (P <0.01) but not to the epithelium-independent agonist nitroprusside (P = 0.37). *P < 0.05 versus epithelium-intact control.
×
Figure 3. Comparison of the responses of (A) the bronchial segments to constrictive agents: 10 micro Meter 5-hydroxytryptamine, 1 micro Meter U46619, 1 micro Meter histamine, or 100 mM KCl; and (B) the 5-hydroxytryptamine-preconstricted bronchial segments to 2% isoflurane or 2% halothane after 30 min of equilibration versus after 90 min of equilibration. There was no significant difference between the two time points, demonstrating stability of the bronchomotor response over time.
Figure 3. Comparison of the responses of (A) the bronchial segments to constrictive agents: 10 micro Meter 5-hydroxytryptamine, 1 micro Meter U46619, 1 micro Meter histamine, or 100 mM KCl; and (B) the 5-hydroxytryptamine-preconstricted bronchial segments to 2% isoflurane or 2% halothane after 30 min of equilibration versus after 90 min of equilibration. There was no significant difference between the two time points, demonstrating stability of the bronchomotor response over time.
Figure 3. Comparison of the responses of (A) the bronchial segments to constrictive agents: 10 micro Meter 5-hydroxytryptamine, 1 micro Meter U46619, 1 micro Meter histamine, or 100 mM KCl; and (B) the 5-hydroxytryptamine-preconstricted bronchial segments to 2% isoflurane or 2% halothane after 30 min of equilibration versus after 90 min of equilibration. There was no significant difference between the two time points, demonstrating stability of the bronchomotor response over time.
×
Figure 4. Relaxation of the 5-hydroxytryptamine-preconstricted bronchial segments to increasing concentrations of isoflurane: control, after epithelial rubbing, after pretreatment with NG-nitro-L-arginine (L-NNA), or after pretreatment with indomethacin. Isoflurane-mediated bronchodilation was significantly attenuated after epithelial rubbing (P < 0.01) or after pretreatment with L-NNA (P <0.005) or indomethacin (P < 0.02). Attenuation after L-NNA was significantly greater than after indomethacin (P < 0.05). #P < 0.05 versus control. *P < 0.05 between L-NNA pretreatment and indomethacin pretreatment. (One minimum alveolar concentration of isoflurane in rats was considered 1.20%. [17 ])
Figure 4. Relaxation of the 5-hydroxytryptamine-preconstricted bronchial segments to increasing concentrations of isoflurane: control, after epithelial rubbing, after pretreatment with NG-nitro-L-arginine (L-NNA), or after pretreatment with indomethacin. Isoflurane-mediated bronchodilation was significantly attenuated after epithelial rubbing (P < 0.01) or after pretreatment with L-NNA (P <0.005) or indomethacin (P < 0.02). Attenuation after L-NNA was significantly greater than after indomethacin (P < 0.05). #P < 0.05 versus control. *P < 0.05 between L-NNA pretreatment and indomethacin pretreatment. (One minimum alveolar concentration of isoflurane in rats was considered 1.20%. [17])
Figure 4. Relaxation of the 5-hydroxytryptamine-preconstricted bronchial segments to increasing concentrations of isoflurane: control, after epithelial rubbing, after pretreatment with NG-nitro-L-arginine (L-NNA), or after pretreatment with indomethacin. Isoflurane-mediated bronchodilation was significantly attenuated after epithelial rubbing (P < 0.01) or after pretreatment with L-NNA (P <0.005) or indomethacin (P < 0.02). Attenuation after L-NNA was significantly greater than after indomethacin (P < 0.05). #P < 0.05 versus control. *P < 0.05 between L-NNA pretreatment and indomethacin pretreatment. (One minimum alveolar concentration of isoflurane in rats was considered 1.20%. [17 ])
×
Figure 5. Relaxation of the 5-hydroxytryptamine-preconstricted bronchial segments to increasing concentrations of halothane: control, after epithelial rubbing, after pretreatment with NG-nitro-L-arginine (L-NNA), or after pretreatment with indomethacin. Halothane-mediated bronchodilation was significantly attenuated after epithelial rubbing (P < 0.01) or after pretreatment with L-NNA (P <0.05) or indomethacin (P < 0.001). Attenuation after L-NNA was significantly less than after indomethacin (P < 0.01). #P < 0.05 versus control. *P < 0.05 between L-NNA pretreatment and indomethacin pretreatment. (One minimum alveolar concentration of halothane in rats was considered 0.88%. [17 ])
Figure 5. Relaxation of the 5-hydroxytryptamine-preconstricted bronchial segments to increasing concentrations of halothane: control, after epithelial rubbing, after pretreatment with NG-nitro-L-arginine (L-NNA), or after pretreatment with indomethacin. Halothane-mediated bronchodilation was significantly attenuated after epithelial rubbing (P < 0.01) or after pretreatment with L-NNA (P <0.05) or indomethacin (P < 0.001). Attenuation after L-NNA was significantly less than after indomethacin (P < 0.01). #P < 0.05 versus control. *P < 0.05 between L-NNA pretreatment and indomethacin pretreatment. (One minimum alveolar concentration of halothane in rats was considered 0.88%. [17])
Figure 5. Relaxation of the 5-hydroxytryptamine-preconstricted bronchial segments to increasing concentrations of halothane: control, after epithelial rubbing, after pretreatment with NG-nitro-L-arginine (L-NNA), or after pretreatment with indomethacin. Halothane-mediated bronchodilation was significantly attenuated after epithelial rubbing (P < 0.01) or after pretreatment with L-NNA (P <0.05) or indomethacin (P < 0.001). Attenuation after L-NNA was significantly less than after indomethacin (P < 0.01). #P < 0.05 versus control. *P < 0.05 between L-NNA pretreatment and indomethacin pretreatment. (One minimum alveolar concentration of halothane in rats was considered 0.88%. [17 ])
×
Figure 6. Relaxation of the 5-hydroxytryptamine-preconstricted bronchial segments to increasing concentrations of isoflurane or halothane expressed as minimum alveolar concentration multiples (MAC). The two anesthetics appear to be equipotent bronchodilators at equivalent MAC multiples. (One MAC in rats was considered 1.20% isoflurane or 0.88% halothane. [17 ])
Figure 6. Relaxation of the 5-hydroxytryptamine-preconstricted bronchial segments to increasing concentrations of isoflurane or halothane expressed as minimum alveolar concentration multiples (MAC). The two anesthetics appear to be equipotent bronchodilators at equivalent MAC multiples. (One MAC in rats was considered 1.20% isoflurane or 0.88% halothane. [17])
Figure 6. Relaxation of the 5-hydroxytryptamine-preconstricted bronchial segments to increasing concentrations of isoflurane or halothane expressed as minimum alveolar concentration multiples (MAC). The two anesthetics appear to be equipotent bronchodilators at equivalent MAC multiples. (One MAC in rats was considered 1.20% isoflurane or 0.88% halothane. [17 ])
×
Table 1. Percent Contraction (Percent Decrease in Diameter from Baseline Equilibration Diameter) to KCl (Viability Testing) and to 5-HR 10 micro Meter (Preconstriction) of Various Experimental Groups of Rat Bronchial Segments 
Image not available
Table 1. Percent Contraction (Percent Decrease in Diameter from Baseline Equilibration Diameter) to KCl (Viability Testing) and to 5-HR 10 micro Meter (Preconstriction) of Various Experimental Groups of Rat Bronchial Segments 
×